Table 3 Share (%) of reimbursed ultra-orphan, oncology orphan and other orphan drugs by type of HTA recommendation, by country
From: The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
All orphan (101) | Ultra-orphan | Oncology orphan | Non-ultra, non-oncology orphan drugs | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Conditional | Negative | Not assessed | Positive | Conditional | Negative | Not assessed | Positive | Conditional | Negative | Not assessed | Positive | Conditional | Negative | Not assessed | |
England | 25 % | 0 % | 14 % | 11 % | 0 % | 0 % | 0 % | 24 % | 33 % | 0 % | 0 % | 0 % | 20 % | 0 % | 50 % | 12 % |
Germany | 76 % | 0 % | 0 % | 1 % | 100 % | 0 % | 0 % | 0 % | 73 % | 0 % | 0 % | 0 % | 77 % | 0 % | 0 % | 3 % |
Poland | 71 % | 69 % | 31 % | 6 % | 100 % | 100 % | 50 % | 27 % | 100 % | 67 % | 38 % | 0 % | 33 % | 57 % | 17 % | 3 % |
Netherlands | 20 % | 75 % | 40 % | 10 % | 0 % | 75 % | 100 % | 8 % | 0 % | 83 % | 33 % | 17 % | 33 % | 72 % | 0 % | 7 % |
Sweden | 100 % | 0 % | 0 % | 0 % | 100 % | 0 % | 0 % | 0 % | 100 % | 0 % | 0 % | 0 % | 100 % | 0 % | 0 % | 0 % |
Scotland | 19 % | 0 % | 10 % | 5 % | 40 % | 0 % | 20 % | 13 % | 9 % | 0 % | 0 % | 8 % | 19 % | 0 % | 14 % | 0 % |
Wales | 32 % | 0 % | 12 % | 6 % | 60 % | 0 % | 0 % | 20 % | 13 % | 0 % | 10 % | 0 % | 29 % | 0 % | 16 % | 7 % |
France | 30 % | 0 % | 25 % | 0 % | 18 % | 0 % | 0 % | 0 % | 36 % | 0 % | 0 % | 0 % | 35 % | 0 % | 25 % | 0 % |
All countriesa | 49 % | 54 % | 16 % | 5 % | 53 % | 67 % | 19 % | 11 % | 46 % | 41 % | 14 % | 4 % | 49 % | 57 % | 17 % | 5 % |